Other research involving NCCN members

International Collaborative Clinical Trials

Click here to learn more about clinical trials.

 

Current New Zealand Research

Dental Late Effects of Oncology Treatment of Children in New Zealand

Anti-neoplastic therapy for children suffering from malignancies can result in dental anomalies such as enamel defects, microdontia, root shortening and missing permanent teeth. This project aims to clinically and radiographically examine the oral health and presence of dental anomalies associated with oncology treatment and to determine the impact of such anomalies.

 

Attempts will be made to determine if specific neo-plastic agents, types of treatment and age of initial diagnosis allows oncologists and dentists to predict the likelihood of dental abnormalities in children who are undergoing cancer treatment.

 

For further information contact:

Dr Erin Mahoney

Specialist Paediatric Dentist

Hutt Valley DHB

Erin.Mahoney@huttvalleydhb.org.nz

Developing a Model of Care for the Long-term Follow-up of Childhood Cancer Survivors

During survivorship, issues related to cancer treatment diminish in importance as other issues, such as the management of late effects, rehabilitation, health promotion and psychology support, increase. This Australasian qualitative study delineated the preferences, unmet needs and barriers experienced by this survivorship group, in order to develop a gold standard service specification for the growing number of survivors of childhood cancer. Papers have been published, and will continue to be published as a result.

 

For further information contact:

Erin Kavanagh

Late Effects Clinical Nurse Specialist, Starship Blood and Cancer Centre

EKavanagh@adhb.govt.nz

Returning to Social Activities /Education after Cancer Diagnosis

There are currently no international guidelines regarding when children should return to social activities following a cancer diagnosis. NCCN and the Child Cancer Foundation are jointly funding a study on the advice given in New Zealand to families with acute lymphoblastic leukaemia (ALL) about infection risks and the decisions they make about the timing of returning to social activities, including schooling.

 

From June 2018, the families of children diagnosed with ALL between 2014 and 2016, aged 2–13 at diagnosis were invited to participate in the study. Their participation involved granting the researchers access to their child’s medical and educational attendance records. During September and October, a representative sample of caregivers (25 in total) was interviewed about their experiences navigating infection risks and returning to social activities. In addition, clinicians and family support workers were invited to complete an online questionnaire about the advice they give to families regarding returning to social activities and infection risks.

 

The study findings will be used by NCCN to develop nationwide guidelines for advice on infection control and timing of returning to social activities provided to families following a cancer diagnosis.

 

As at June 2019 all the data has been gathered and analysed for the project, with the next steps being writing up the results, and disseminating the findings.

For further information contact:

Dr. Claire Gooder, Researcher

research@childcancer.org.nz

The Margaret Lewis Study

International research has shown that child cancer survivors are at greater risk of developing subsequent malignancies and of ‘late mortality’ in adulthood due to causes which may be linked to their childhood cancer and its treatment.

 

Dr Margaret Lewis was a Wellington-based paediatrician who was instrumental in establishing a national children’s cancer database in the 1980s – the predecessor of the New Zealand Children’s Cancer Registry (NZCCR).

 

The NZCCR Working Group is undertaking a comprehensive analysis of the Margaret Lewis dataset in order to determine the incidence and survival of children diagnosed with cancer in New Zealand between 1978 and 1999, including the incidence of second malignancies and cause-specific mortality.

 

For further information contact:

Kirsten Ballantine

NZCCR Manager

Children’s Haematology Oncology Centre

kirsten.ballantine@cdhb.health.nz

Precision Paediatric Cancer Project (PPCP)

The Precision Paediatric Cancer Project (PPCP) was launched in 2018 and uses Next-Generation Sequencing (NGS) to identify gene mutations in the cancers of eligible children and adolescents.

 

The five-year project builds advanced clinical capacity in New Zealand to allow new targeted treatment options to be identified in children aged 0-18 years, where standard treatment options are ineffective.

 

The clinical trial is at Starship Blood and Cancer Centre (Auckland), and the Children’s Haematology and Oncology Centre (Christchurch) but will be available to all eligible child cancer patients, no matter where they live in the country.

 

Cure Kids and Child Cancer Foundation have jointly committed $1.25 million to the PPCP.

Research Publications

Journal Publications
Conference Posters & Presentations
Summer Studentship Projects

Each year the University of Otago, Christchurch School of Medicine and the University of Auckland host Summer Studentship Programmes. Staff at the Children’s Haematology Oncology Centre and the Starship Blood and Cancer Centre have the opportunity to supervise projects to further our understanding of childhood cancer. These projects also benefit the participating students, introducing them to the excitement and challenge of research in a field which they are interested in.

 

 

Research Funding Opportunities

Click here to find out more about research opportunities.